Source:http://linkedlifedata.com/resource/pubmed/id/20966170
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2011-1-21
|
| pubmed:abstractText |
Treatment outcome of acute myeloid leukemia (AML) in elderly patients remains unsatisfactory. It has been shown that the infusion of granulocyte colony-stimulating factor-mobilized donor peripheral blood stem cells (G-PBSCs) can enhance graft-versus-leukemia effects and speed hematopoietic recovery. Fifty-eight AML patients aged 60-88 years were randomly assigned to receive induction chemotherapy with cytarabine and mitoxantrone (control group; n = 28) or it plus human leukocyte antigen-mismatched G-PBSCs (G-PBSC group; n = 30). Patients who achieved complete remission received another 2 cycles of postremission therapy with intermediate-dose cytarabine or it plus G-PBSCs. The complete remission rate was significantly higher in the G-PBSC group than in the control group (80.0% vs 42.8%; P = .006). The median recovery times of neutrophils and platelets were 11 days and 14.5 days, respectively, in the G-PBSC group and 16 days and 20 days, respectively, in the control group after chemotherapy. The 2-year probability of disease-free survival was significantly higher in the G-PBSC group than in the control group (38.9% vs 10.0%; P = .01). No graft-versus-host disease was observed in any patient. Persistent donor microchimerism was successfully detected in all of the 4 female patients. These results indicate that G-PBSCs in combination with conventional chemotherapy may provide a promising treatment method for AML in elderly patients.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:AiHui-ShengHS,
pubmed-author:DongZhengZ,
pubmed-author:FuY PYP,
pubmed-author:GuoMeiM,
pubmed-author:HuKai-XunKX,
pubmed-author:HuangYa-JingYJ,
pubmed-author:LiuGuang-XianGX,
pubmed-author:QiaoJian-HuiJH,
pubmed-author:QiaoJun-XiaoJX,
pubmed-author:SunQi-YunQY,
pubmed-author:SunWan-JunWJ,
pubmed-author:SunXue-DongXD,
pubmed-author:WangDan-HongDH,
pubmed-author:YuChang-LinCL
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
20
|
| pubmed:volume |
117
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
936-41
|
| pubmed:meshHeading |
pubmed-meshheading:20966170-Acute Disease,
pubmed-meshheading:20966170-Adult,
pubmed-meshheading:20966170-Aged,
pubmed-meshheading:20966170-Aged, 80 and over,
pubmed-meshheading:20966170-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20966170-Cytarabine,
pubmed-meshheading:20966170-Female,
pubmed-meshheading:20966170-HLA Antigens,
pubmed-meshheading:20966170-Histocompatibility,
pubmed-meshheading:20966170-Histocompatibility Testing,
pubmed-meshheading:20966170-Humans,
pubmed-meshheading:20966170-Infection,
pubmed-meshheading:20966170-Leukemia, Myeloid,
pubmed-meshheading:20966170-Male,
pubmed-meshheading:20966170-Middle Aged,
pubmed-meshheading:20966170-Mitoxantrone,
pubmed-meshheading:20966170-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:20966170-Transplantation Chimera,
pubmed-meshheading:20966170-Treatment Outcome
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients.
|
| pubmed:affiliation |
Department of Hematology and Transplantation, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|